Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

Recruiting now · Phase 4

Conditions studied: Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease

In brief

Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.

Key facts

Study ID

NCT04588077

Run by

Mercy Medical Center

People needed

200

Starts

2020-09-14

Expected to finish

2028-12-01

Last updated by the study team

2024-11-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All the cirrhosis patients more than 18 years old presented to the hepatology clinic in Mercy Medical Center between 09/2020 and 07/2021 who do not have immunity against Hepatitis B (defined as anti-HBs titer < 10 mIU/ml) will be recruited.

You may not qualify if…

• Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive the hepatitis B vaccine.
• Those who had previous exposure to hepatitis B.
• Post liver transplant patients.
• Less than 18 years old.

Where it is running

• Mercy Medical Center — Baltimore, Maryland, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.